Strong Or Moderate Cyp3a Inducers + Quizartinib Interaction
Majorinteraction on record
Description
Concomitant use decreases quizartinib systemic exposure, which may reduce VANFLYTA efficacy. Concomitant use should be avoided.
Mechanism
CYP3A induction decreases systemic exposure
Source: NLP:quizartinib